Human papillomavirus testing: the challenges of picking the right tools for the job

References

• zur Hausen H. Papillomaviruses in the causation of human cancers – a brief historical account. Virology384(2), 260–265 (2009).
   PubMed Web of Science ®Google Scholar
• Bernard HU, Burk RD, Chen Z, van Doorslaer K, Hausen H, de Villiers EM. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology401(1), 70–79 (2010).
   PubMed Web of Science ®Google Scholar
• Bouvard V, Baan R, Straif K et al.; WHO International Agency for Research on Cancer Monograph Working Group. A review of human carcinogens – Part B: biological agents. Lancet Oncol.10(4), 321–322 (2009).
   PubMed Web of Science ®Google Scholar
• Khan MJ, Castle PE, Lorincz AT et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J. Natl Cancer Inst.97(14), 1072–1079 (2005).
   PubMed Web of Science ®Google Scholar
• Stoler MH, Wright TC Jr, Sharma A, Apple R, Gutekunst K, Wright TL; ATHENA (Addressing The Need for Advanced HPV Diagnostics) HPV Study Group. High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study. Am. J. Clin. Pathol.135(3), 468–475 (2011).
   PubMed Web of Science ®Google Scholar
• Cuzick J, Ambroisine L, Cadman L et al. Performance of the Abbott RealTime high-risk HPV test in women with abnormal cervical cytology smears. J. Med. Virol.82(7), 1186–1191 (2010).
   PubMedGoogle Scholar
• Insinga RP, Perez G, Wheeler CM et al.; FUTURE I Investigators. Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women. Cancer Epidemiol. Biomarkers Prev.19(6), 1585–1594 (2010).
   PubMed Web of Science ®Google Scholar
• Kjær SK, Frederiksen K, Munk C, Iftner T. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J. Natl Cancer Inst.102(19), 1478–1488 (2010).
   PubMedGoogle Scholar
• Accardi R, Rubino R, Scalise M et al. E6 and E7 from human papillomavirus type 16 cooperate to target the PDZ protein Na/H exchange regulatory factor 1. J. Virol.85(16), 8208–8216 (2011).
   Google Scholar
• Pim D, Banks L. Interaction of viral oncoproteins with cellular target molecules: infection with high-risk vs low-risk human papillomaviruses. APMIS118(6–7), 471–493 (2010).
   PubMed Web of Science ®Google Scholar
• Stanley M. HPV – immune response to infection and vaccination. Infect. Agent. Cancer20, 5–19 (2010).
   Google Scholar
• Poljak M, Kocjan BJ. Commercially available assays for multiplex detection of alpha human papillomaviruses. Expert Rev. Anti. Infect. Ther.8(10), 1139–1162 (2010).
   PubMed Web of Science ®Google Scholar
• Arbyn M, Ronco G, Cuzick J, Wentzensen N, Castle PE. How to evaluate emerging technologies in cervical cancer screening?. Int. J. Cancer125(11), 2489–2496 (2009).
   PubMed Web of Science ®Google Scholar
• Meijer CJ, Berkhof J, Castle PE et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int. J. Cancer124(3), 516–520 (2009).
   PubMed Web of Science ®Google Scholar
• Tabrizi SN. Quality assessment for human papillomavirus testing. Sex. Health7(3), 335–337 (2010).
   Google Scholar
• Fagan EJ, Moore C, Jenkins C, Rossouw A, Cubie HA, James VL. External quality assessment for molecular detection of human papillomaviruses. J. Clin. Virol.48(4), 251–254 (2010).
   Google Scholar
• Eklund C, Zhou T, Dillner J; WHO Human Papillomavirus Laboratory Network. Global proficiency study of human papillomavirus genotyping. J. Clin. Microbiol.48(11), 4147–4155 (2010).
   Google Scholar
• Cuzick J, Arbyn M, Sankaranarayanan Tsu V et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine26(Suppl. 19), K29–K41 (2008).
   PubMed Web of Science ®Google Scholar
• Nanda K, McCrory DC, Myers ER et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann. Intern. Med.132, 810–819 (2000).
   PubMed Web of Science ®Google Scholar
• Castle PE, Stoler MH, Wright TC, Sharma A, Wright TL, Behrens C. Performance of carcinogenic HPV testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. Lancet Oncol.12(9), 880–890 (2011).
   PubMed Web of Science ®Google Scholar
• Melnikow J, Nuovo J, Willan AR, Chan BK, Howell LP. Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet. Gynecol.92(4 Pt 2), 727–735 (1998).
   PubMed Web of Science ®Google Scholar
• Kyrgiou M, Koliopoulos G, Martin-Hirsch P et al. Management of minor cervical cytological abnormalities: a systematic review and a meta-analysis of the literature. Cancer Treat. Rev.33(6), 514–520 (2007).
   Google Scholar
• Arbyn M, Martin-Hirsch P, Buntinx F, Van Ranst M, Paraskevaidis E, Dillner J. Triage of women with equivocal or low-grade cervical cytology results: a meta-analysis of the HPV test positivity rate. J. Cell. Mol. Med.13(4), 648–659 (2009).
   PubMed Web of Science ®Google Scholar
• Sargent A, Bailey A, Turner A et al. Optimal threshold for a positive hybrid capture 2 test for detection of human papillomavirus: data from the ARTISTIC trial. J. Clin. Microbiol.48(2), 554–558 (2010).
   PubMedGoogle Scholar
• Ratnam S, Coutlee F, Fontaine D et al. Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancer. J. Clin. Microbiol.49(2), 557–564 (2011).
   PubMed Web of Science ®Google Scholar
• Cuschieri K, Wentzensen N. Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Cancer Epidemiol. Biomarkers Prev.17(10), 2536–2545 (2008).
   PubMed Web of Science ®Google Scholar
• Tsoumpou I, Arbyn M, Kyrgiou M et al. p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis. Cancer Treat. Rev.35(3), 210–220 (2009).
   PubMed Web of Science ®Google Scholar
• Szarewski A, Ambroisine L, Cadman L et al. Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol. Biomarkers Prev.17(11), 3033–3042 (2008).
   PubMed Web of Science ®Google Scholar
• Katki HA, Kinney WK, Fetterman B et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol.12(7), 663–672 (2011).
   PubMed Web of Science ®Google Scholar
• Kitchener HC, Almonte M, Thomson C et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomized controlled trial. Lancet Oncol.10(7), 672–682 (2009).
   PubMed Web of Science ®Google Scholar
• Arbyn M. HPV testing to monitor outcome after treatment of high-grade CIN. Presented at: 28th International Papillomavirus Meeting. Malmo, Sweden, 8–14 May 2009.
   Google Scholar
• Strander B, Andersson-Ellstrom A, Milsom I, Sparen P. Long term risk of invasive cancer after treatment for cervical intraepithelial neoplasia grade 3: a population based cohort study. BMJ335(7629), 1077 (2007).
   Google Scholar
• Kocken M, Helmerhorst TJM, Berkhof J et al. Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study. Lancet Oncol.12, 441–450 (2011).
   PubMed Web of Science ®Google Scholar
• Valasoulis G, Koliopoulos G, Founta C et al. Alterations in human papillomavirus-related biomarkers after treatment of cervical intraepithelial neoplasia. Gynecol. Oncol.121(1), 43–48 (2011).
   Google Scholar
• Venturoli S, Ambretti S, Cricca M et al Correlation of high-risk human papillomavirus genotypes persistence and risk of residual or recurrent cervical disease after surgical treatment. J. Med. Virol.80(8), 1434–1440 (2008).
   PubMed Web of Science ®Google Scholar
• Brismar S, Johansson B, Borjesson M, Arbyn M, Andersson S. Follow-up after treatment of cervical intraepithelial neoplasia by human papillomavirus genotyping. Am. J. Obstet. Gynecol.201(1), 17.e1–8 (2009).
   Google Scholar
• Kotaniemi-Talonen L, Nieminen P, Anttila A, Hakama M. Routine cervical screening with primary HPV testing and cytology triage protocol in a randomized setting. Br. J. Cancer93(8), 862–867 (2005).
   PubMed Web of Science ®Google Scholar
• Sankaranarayanan R, Nene BM, Dinshaw KA et al. A cluster randomized controlled trial of visual, cytology and human papillomavirus screening for cancer of the cervix in rural India. Int. J. Cancer116, 617–623 (2005).
   PubMed Web of Science ®Google Scholar
• Ronco G, Segnan N, Giorgi-Rossi P et al. Human papillomavirus testing and liquid-based cytology: results at recruitment from the New Technologies for Cervical Cancer Randomized Controlled Trial. J. Natl Cancer Inst.98, 765–774 (2006).
   PubMed Web of Science ®Google Scholar
• Ronco G, Giorgi-Rossi P, Carozzi F et al. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomized controlled trial. Lancet Oncol.7, 547–555 (2006).
   PubMedGoogle Scholar
• Bulkmans NWJ, Berkhof J, Rozendaal L et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomized controlled implementation trial. Lancet370, 1764–1772 (2007).
   PubMed Web of Science ®Google Scholar
• Naucler P, Ryd W, Tornberg S et al. Human papillomavirus and papanicolaou tests to screen for cervical cancer. N. Engl. J. Med.357, 1589–1597 (2007).
   PubMed Web of Science ®Google Scholar
• Ogilvie GS, van Niekerk DJ, Krajden M et al. A randomized controlled trial of Human Papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary results (HPV FOCAL trial). BMC Cancer10, 111 (2010).
   PubMedGoogle Scholar
• Almonte M, Sasieni P, Cuzick J. Incorporating human papillomavirus testing into cytological screening in the era of prophylactic vaccines. Best Pract. Res. Clin. Obstet. Gynaecol.25(5), 617–629 (2011).
   Google Scholar
• Cuzick J, Clavel C, Petry KU et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int. J. Cancer119(5), 1095–1101 (2006).
   PubMed Web of Science ®Google Scholar
• Saraiya M, Berkowitz Z, Yabroff KR, Wideroff L, Kobrin S, Benard V. Cervical cancer screening with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone: what screening intervals are physicians recommending?. Arch. Intern. Med.170(11), 977–985 (2010).
   Google Scholar
• Schmeink CE, Bekkers RL, Massuger LF, Melchers WJ. The potential role of self-sampling for high-risk human papillomavirus detection in cervical cancer screening. Rev. Med. Virol.3, 139–153 (2011).
   Google Scholar
• Rebolj M, Bonde J, Njor SH, Lynge E. Human papillomavirus testing in primary cervical screening and the cutoff level for hybrid capture 2 tests: systematic review. BMJ342, d2757 (2011).
   PubMedGoogle Scholar
• Rijkaart DC, Berkhof J, van Kemenade FJ et al. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int. J. Cancer DOI: 10.1002/ijc.26056 (2011) (Epub ahead of print).
   PubMedGoogle Scholar
• Carozzi F, Confortini M, Dalla Palma P et al. New Technologies for Cervical Cancer Screening (NTCC) Working Group. Use of p16-INK4A overexpression to increase the specificity of human papillomavirus testing: a nested substudy of the NTCC randomized controlled trial. Lancet Oncol.10, 937–945 (2008).
   Google Scholar
• Hoots BE, Palefsky JM, Pimenta JM, Smith JS. Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. Int. J. Cancer124(10), 2375–2383 (2009).
   PubMed Web of Science ®Google Scholar
• Miralles-Guri C, Bruni L, Cubilla AL, Castellsagué X, Bosch FX, de Sanjosé S. Human papillomavirus prevalence and type distribution in penile carcinoma. J. Clin. Pathol.62(10), 870–878 (2009).
   PubMed Web of Science ®Google Scholar
• Chung CH, Gillison ML. Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications. Clin. Cancer Res.15(22), 6758–6762 (2009).
   PubMed Web of Science ®Google Scholar
• Salit IE, Lytwyn A, Raboud J et al. The role of cytology (Pap tests) and human papillomavirus testing in anal cancer screening. AIDS24(9), 1307–1131 (2010).
   PubMed Web of Science ®Google Scholar
• Elbasha EH, Dasbach EJ. Impact of vaccinating boys and men against HPV in the United States. Vaccine28(42), 6858–6867 (2010).
   PubMed Web of Science ®Google Scholar
• Giuliano AR, Lee JH, Fulp W et al. Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet377(9769), 932–940 (2011).
   PubMed Web of Science ®Google Scholar
• Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J. Infect. Dis.202(12), 1789–1799 (2010).
   PubMed Web of Science ®Google Scholar
• Zhao FH, Lin MJ, Chen F et al.; Cervical Cancer Screening Group in China. Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China. Lancet Oncol.12, 1160–1171 (2010).
   Google Scholar
• Sasieni P, Castanon A, Cuzick J. Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. BMJ339, b2968 (2009).
   PubMedGoogle Scholar
• Sankaranarayanan R, Boffetta P. Research on cancer prevention, detection and management in low- and medium-income countries. Ann Oncol.21(10), 1935–1943 (2010).
   PubMed Web of Science ®Google Scholar
• Denny L, Kuhn L, De Souza M, Pollack AE, Dupree W, Wright TC Jr. Screen-and-treat approaches for cervical cancer prevention in low-resource settings: a randomized controlled trial. JAMA294(17), 2173–2181 (2005).
   PubMed Web of Science ®Google Scholar
• Shi JF, Canfell K, Lew JB et al. Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: an epidemiologic and cost–effectiveness modelling study. BMC Cancer11, 239 (2011).
   Google Scholar
• Sankaranarayanan R, Nene BM, Shastri SS et al. HPV screening for cervical cancer in rural India. N. Engl. J. Med.360(14), 1385–1394 (2009).
   PubMed Web of Science ®Google Scholar
• Qiao YL, Sellors JW, Eder PS et al. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol.9(10), 929–936 (2008).
   PubMed Web of Science ®Google Scholar
• Virtanen A, Nieminen P, Luostarinen T, Anttila A. Self-sample HPV tests as an intervention for nonattendees of cervical cancer screening in Finland: a randomized trial. Cancer Epidemiol. Biomarkers Prev.9, 1960–1969 (2011).
   Google Scholar
• Wikström I, Lindell M, Sanner K, Wilander E. Self-sampling and HPV testing or ordinary Pap-smear in women not regularly attending screening: a randomized study. Br. J. Cancer105(3), 337–339 (2011).
   PubMed Web of Science ®Google Scholar
• Szarewski A, Cadman L, Mesher D et al. HPV self-sampling as an alternative strategy in non-attenders for cervical screening – a randomized controlled trial. Br. J. Cancer104(6), 915–920 (2011).
   PubMed Web of Science ®Google Scholar
• Howard M, Lytwyn A, Lohfeld L, Redwood-Campbell L, Fowler N, Karwalajtys T. Barriers to acceptance of self-sampling for human papillomavirus across ethnolinguistic groups of women. Can. J. Public Health.100(5), 365–369 (2009).
   PubMed Web of Science ®Google Scholar
• Waller J, McCaffery K, Forrest S et al. Acceptability of unsupervised HPV self-sampling using written instructions. J. Med. Screen.13(4), 208–213 (2006).
   PubMedGoogle Scholar
• Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, Gertig DM. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet377(9783), 2085–2092 (2011).
   PubMed Web of Science ®Google Scholar
• Franco EL, Cuzick J. Cervical cancer screening following prophylactic human papillomavirus vaccination. Vaccine26(Suppl. 1), A16–A23 (2008).
   PubMed Web of Science ®Google Scholar
• Almonte M, Murillo R, Sánchez GI et al. New paradigms and challenges in cervical cancer prevention and control in Latin America. Salud. Publica Mex.52(6), 544–559 (2010).
   Google Scholar